EQS-News: Benzinga / Key word (s): Science Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And ...

In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma ... as well as multiple early-stage programs ...

Also, regarding HyBryte (TM), in October 2024, Soligenix announced that the Hong Kong Patent Office had granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin." Synthetic ...

Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety ...

Years of translational research have successfully improved treatment outcomes for common dermatological conditions such as ...